- Home
- SSL vs APLS Comparison
SSL vs APLS Comparison
Compare SSL & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSL
- APLS
- Stock Information
- Founded
- SSL 1950
- APLS 2009
- Country
- SSL South Africa
- APLS United States
- Employees
- SSL N/A
- APLS N/A
- Industry
- SSL Oil & Gas Production
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- SSL Energy
- APLS Health Care
- Exchange
- SSL Nasdaq
- APLS Nasdaq
- Market Cap
- SSL 4.6B
- APLS 4.4B
- IPO Year
- SSL N/A
- APLS 2017
- Fundamental
- Price
- SSL $4.91
- APLS $34.63
- Analyst Decision
- SSL
- APLS Buy
- Analyst Count
- SSL 0
- APLS 19
- Target Price
- SSL N/A
- APLS $49.89
- AVG Volume (30 Days)
- SSL 969.2K
- APLS 3.6M
- Earning Date
- SSL 01-01-0001
- APLS 11-05-2024
- Dividend Yield
- SSL 2.13%
- APLS N/A
- EPS Growth
- SSL N/A
- APLS N/A
- EPS
- SSL N/A
- APLS N/A
- Revenue
- SSL $15,070,363,793.00
- APLS $715,216,000.00
- Revenue This Year
- SSL N/A
- APLS $95.53
- Revenue Next Year
- SSL $5.64
- APLS $12.94
- P/E Ratio
- SSL N/A
- APLS N/A
- Revenue Growth
- SSL N/A
- APLS 162.10
- 52 Week Low
- SSL $4.84
- APLS $24.34
- 52 Week High
- SSL $10.28
- APLS $73.80
- Technical
- Relative Strength Index (RSI)
- SSL 39.32
- APLS 60.79
- Support Level
- SSL $4.97
- APLS $31.76
- Resistance Level
- SSL $5.08
- APLS $34.98
- Average True Range (ATR)
- SSL 0.16
- APLS 1.59
- MACD
- SSL 0.02
- APLS -0.07
- Stochastic Oscillator
- SSL 10.64
- APLS 69.95
About SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main segments: Energy business and Chemical business. It generates maximum revenue from the Chemicals segment. The company operates coal mines and its upstream interests in oil and gas, both of which are used as feedstock in the company's energy and chemicals operations. Sasol markets commodity and performance chemicals, sells liquid fuel products, and markets, distributes and transports pipeline gas. Geographically the company generates the majority of its revenue from South Africa.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.